Biotech & Life Sciences
16 Billion in Growth? Inside the Rapid Rise of Wire-Free Coronary Physiology
Large-Scale Medicare Study Validates CathWorks FFRangio Outcomes Through Two Years At the Cardiovascular Research Technologies (CRT) 2026 conference in Washington, D.C., researchers presented the first-ever United States Medicare data comparing angiography-derived physiology (ADP) to traditional invasive methods. The study, led by Dr. Christopher Chieh Yang Koo and investigators from Harvard Medical School, analyzed over 4,000…
SkinCure Oncology Sues Federal Government: The Fight for “Scalpel-Free” Cancer Care
SkinCure Oncology, the provider of a popular nonsurgical skin cancer treatment known as Image-Guided SRT, announced on March 6, 2026, that it has filed a lawsuit in federal court. The company is seeking an emergency injunction to stop new Medicare policies that would significantly limit patient access to this technology. The lawsuit specifically names the…
Can You Drink Your Way to Better Skin? Vital Proteins Debuts New Collagen Water
Transforming Daily Hydration with Science-Backed Bioactive Peptides Vital Proteins, the industry leader in collagen supplementation, officially debuted its latest innovation on March 4, 2026: Vital Proteins Collagen Sparkling Water. This launch represents a strategic pivot into the high-growth ready-to-drink (RTD) functional beverage space; it offers consumers a “beauty-from-within” solution in a convenient, carbonated format. The…
Going Private: Consortium to Acquire Select Medical in $3.9 Billion Cash Deal
The healthcare sector just saw a massive consolidation move from the inside out. On March 2, 2026, Select Medical Holdings Corporation (NYSE: SEM) announced it’s being taken private in a $3.9 billion deal. The architect of the move? A consortium led by the company’s own Executive Chairman and Co-Founder, Robert A. Ortenzio, Senior EVP Martin…
PureHealth Research Debuts “Natural GLP-1 Support” for Needle-Free Weight Care
PureHealth Research has officially entered the metabolic health race with its Natural GLP-1 Support collection. Headlined by the 9-ingredient formula GLP ON, the line aims to provide a needle-free, non-prescription alternative to the high-cost injectable GLP-1 agonists that have dominated the market recently. I’m noticing a strategic shift here. While many “nature’s Ozempic” products rely…
New Hope for PKU: Adolescents 12+ Gain Access to Breakthrough Enzyme Therapy
In a significant expansion of treatment options for the metabolic disease community, the U.S. Food and Drug Administration (FDA) has approved PALYNZIQ® (pegvaliase-pqpz) for pediatric patients 12 years of age and older with Phenylketonuria (PKU). This supplemental approval, announced on February 27, 2026, marks PALYNZIQ as the only enzyme substitution therapy available for this younger…
FDA Clearance: Cara Medical Unveils Noninvasive 3D Mapping for Cardiac Conduction
In a landmark decision for cardiac care, the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Cara Medical Ltd. for its CARA System. This platform is the first of its kind to provide noninvasive, patient-specific 3D visualization of the cardiac conduction system—the internal “electrical wiring” of the heart—using standard CT angiography (CTA)…
Clinical Milestone: Argo Biopharma Reports 100% Attack Reduction in HAE Phase II Trial
In a significant update for the Hereditary Angioedema (HAE) community, Argo Biopharmaceutical has announced positive Phase II interim results for BW-20805, its investigational siRNA therapeutic. The data, presented as a late-breaking abstract at the 2026 AAAAI Annual Meeting, highlights the drug’s potential as a “best-in-class” long-acting prophylactic. I’m seeing a clear shift in the HAE…
Biopharma Partnership: Astellas and Vir Bio Collaborate on Precision Oncology
Astellas Pharma and Vir Biotechnology just announced a global strategic collaboration. The deal centers on VIR-5500, an investigational T-cell engager (TCE) for prostate cancer. I’m looking at the financial terms—it’s a massive commitment. Vir is receiving $335 million upfront with a total deal value potentially hitting $1.7 billion. I see a clear signal here: the…
Johnson & Johnson Reports Long‑Term TREMFYA Data: 80% in Remission
Johnson & Johnson (NYSE:JNJ) has announced new long‑term data from the QUASAR LTE study, showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis. More than 80% of patients were in clinical remission, over 50% achieved endoscopic remission, and nearly 79% showed histo‑endoscopic…
